Biotech Co. Didn't Disclose Rejected Patent, Investors Say
PolarityTE Inc. closed on a $104 million deal to buy a pending patent covering skin regeneration technology without telling investors that the U.S. Patent and Trademark Office had rejected the patent...To view the full article, register now.
Already a subscriber? Click here to view full article